Emerging Science and Management of Atopic Dermatitis
The landscape of atopic dermatitis has evolved rapidly in recent years.
The landscape of atopic dermatitis has evolved rapidly in recent years. The introduction of crisaborole, a phosphodiesterase-4 inhibitor, enables clinicians to offer another nonsteroidal topical therapy to patients with mild to moderate disease. The approval of dupilumab—an interleukin-4 and interleukin-13 inhibitor and the first biologic to become available for the treatment of atopic dermatitis—has revolutionized the therapy of adults with moderate to severe disease.
The impact of atopic dermatitis on patients in terms of symptoms and quality of life has been well characterized in children and their families.
Food allergy is common among children with atopic dermatitis.
A topic dermatitis is a chronic relapsing condition that can have a substantial impact on quality of life.
Most patients with atopic dermatitis may be adequately managed with nonpharmacologic measures (eg, emollients), topical anti-inflammatory therapies, environmental modification (eg, avoiding triggers), and for some, phototherapy.